Glutathione Price Comparison — Compare 22 Vendors
Price Comparison
Compare vendors · per 600mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| Peptyx Labs8.5/10 | $32.00 | $0.0213 | May 26, 2026 | Buy → |
| CertaPeptides7.5/10 | $44.59 | $0.0297 | Jun 27, 2026 | Buy → |
| Puratek Peptides9.5/10 | $46.76 | $0.0312 | May 19, 2026 | Buy → |
| Midwest Peptide8.5/10 | $53.99 | $0.0360 | Jun 18, 2026 | Buy → |
| Woosh Labs8/10 | $53.99 | $0.0360 | Jun 24, 2026 | Buy → |
| Novatherix Laboratories7/10 | $58.49 | $0.0390 | Jun 4, 2026 | Buy → |
Research details
Glutathione — research data
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Overview
About Glutathione
Mechanism of action
Master endogenous antioxidant; neutralizes reactive oxygen species (ROS); regenerates vitamins C and E; supports liver detoxification (Phase II); modulates immune response.
Safety profile
Generally very safe. IV: rare hypersensitivity. High-dose long-term: possible zinc depletion, theoretical melanin suppression. · Endogenous antioxidant; very safe; rare allergic reactions; widely used in IV wellness
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Glutathione below your target.
Related pages
More on Glutathione
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- The landmark Sechi et al. (1996) open-label study in 9 early Parkinson's patients treated with IV glutathione 600 mg twice daily for 30 days reported a ~42% average decline in disability scores, with benefits persisting 2–4 months post-treatment — results that remain unreplicated in larger controlled trials.
- A subsequent randomized, double-blind, placebo-controlled pilot trial (Hauser et al., 2009; 21 patients) found no significant difference in UPDRS motor scores between IV glutathione 1,400 mg three-times-weekly and placebo, though a trend toward mild symptomatic benefit was noted.